Last 12 months
Inside the activity.
0 purchase rows · 75 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 6 |
| Feb 2026 | 0 | 8 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 15 |
| Sep 2026 | 0 | 7 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2020 Filed Jun 16, 2020 22:51 UTC |
Rodriguez JavierDirector
|
GrantRestricted Stock Unit · Derivative | 1,838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-019796 · form4.xml · derivative · entry 2 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,838 Underlying: Common Stock · 1,838 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on June 15, 2021. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on June 15, 2021. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 22:51 UTC |
Rodriguez JavierDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 8,667 | $0.00 Strike: $73.97 | $0.00 |
DisclosureSEC source: 0001127602-20-019796 · form4.xml · derivative · entry 1 Rodriguez Javier · CIK 0001415548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,667 Underlying: Common Stock · 8,667 shares Expires 2030-06-15 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary measured from June 15, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable on June 15, 2021. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 19:28 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019496 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,470 Underlying: Common Stock · 3,646 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 19:28 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 1,691 | $77.07 | $130,325.37 |
DisclosureSEC source: 0001127602-20-019496 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,355 Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 19:28 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019496 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 7, 2020 23:39 UTC |
Horning SandraDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,886 | $0.00 Strike: $77.47 | $0.00 |
DisclosureSEC source: 0001127602-20-015831 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,886 Underlying: Common Stock · 7,886 shares Expires 2030-05-06 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary measured from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 7, 2020 23:39 UTC |
Horning SandraDirector
|
GrantRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015831 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,568 Underlying: Common Stock · 1,936 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 7, 2020 23:50 UTC |
Kramer Kelly A.Director
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,886 | $0.00 Strike: $77.47 | $0.00 |
DisclosureSEC source: 0001127602-20-015833 · form4.xml · derivative · entry 2 Kramer Kelly A. · CIK 0001629885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,886 Underlying: Common Stock · 7,886 shares Expires 2030-05-06 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 7, 2020 23:50 UTC |
Kramer Kelly A.Director
|
GrantRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015833 · form4.xml · derivative · entry 1 Kramer Kelly A. · CIK 0001629885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,730 Underlying: Common Stock · 1,936 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:08 UTC |
BARTON JACQUELINE KDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,886 | $0.00 Strike: $77.47 | $0.00 |
DisclosureSEC source: 0001127602-20-015835 · form4.xml · derivative · entry 2 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,886 Underlying: Common Stock · 7,886 shares Expires 2030-05-06 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:08 UTC |
BARTON JACQUELINE KDirector
|
GrantRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015835 · form4.xml · derivative · entry 1 BARTON JACQUELINE K · CIK 0001183680 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,489 Underlying: Common Stock · 1,936 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:20 UTC |
Lofton Kevin EDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,886 | $0.00 Strike: $77.47 | $0.00 |
DisclosureSEC source: 0001127602-20-015840 · form4.xml · derivative · entry 4 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,886 Underlying: Common Stock · 7,886 shares Expires 2030-05-06 F4 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:20 UTC |
Lofton Kevin EDirector
|
GrantRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015840 · form4.xml · derivative · entry 3 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,830 Underlying: Common Stock · 1,936 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:26 UTC |
WOLD OLSEN PERDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,886 | $0.00 Strike: $77.47 | $0.00 |
DisclosureSEC source: 0001127602-20-015842 · form4.xml · derivative · entry 4 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,886 Underlying: Common Stock · 7,886 shares Expires 2030-05-06 F4 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:26 UTC |
WOLD OLSEN PERDirector
|
GrantRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015842 · form4.xml · derivative · entry 3 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,936 Underlying: Common Stock · 1,936 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:30 UTC |
Whitley Richard JamesDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,886 | $0.00 Strike: $77.47 | $0.00 |
DisclosureSEC source: 0001127602-20-015845 · form4.xml · derivative · entry 4 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,886 Underlying: Common Stock · 7,886 shares Expires 2030-05-06 F4 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:30 UTC |
Whitley Richard JamesDirector
|
GrantRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015845 · form4.xml · derivative · entry 3 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,964 Underlying: Common Stock · 1,936 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:36 UTC |
MANWANI HARISHDirector
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,886 | $0.00 Strike: $77.47 | $0.00 |
DisclosureSEC source: 0001127602-20-015849 · form4.xml · derivative · entry 5 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,886 Underlying: Common Stock · 7,886 shares Expires 2030-05-06 F4 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:36 UTC |
MANWANI HARISHDirector
|
GrantRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015849 · form4.xml · derivative · entry 4 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,936 Underlying: Common Stock · 1,936 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:02 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 650 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001127602-20-015824 · form4.xml · derivative · entry 5 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 650 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:02 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 12,560 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001127602-20-015824 · form4.xml · derivative · entry 4 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,560 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:02 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
SaleCommon Stock | 13,210 | $79.23 | $1,046,640.19 |
DisclosureSEC source: 0001127602-20-015824 · form4.xml · nonDerivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,644 F2 · price: Sale prices reported for the transactions reported here range from $79.23 to $79.24. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:02 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionCommon Stock | 650 | $24.30 | $15,791.75 |
DisclosureSEC source: 0001127602-20-015824 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:02 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionCommon Stock | 12,560 | $40.56 | $509,433.60 |
DisclosureSEC source: 0001127602-20-015824 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 23:17 UTC |
WILSON GAYLE EDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015829 · form4.xml · derivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 5, 2020. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 5, 2020. Read SEC document |
| May 05, 2020 Filed May 7, 2020 23:17 UTC |
WILSON GAYLE EDirector
|
Exercise / conversionCommon Stock | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015829 · form4.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:20 UTC |
Lofton Kevin EDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015840 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,894 Underlying: Common Stock · 2,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested May 5, 2020. F2 · derivative.expiration_date: 100% of the restricted stock units vested May 5, 2020. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:20 UTC |
Lofton Kevin EDirector
|
Exercise / conversionCommon Stock | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015840 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:26 UTC |
WOLD OLSEN PERDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015842 · form4.xml · derivative · entry 2 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 5, 2020. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 5, 2020. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:26 UTC |
WOLD OLSEN PERDirector
|
Exercise / conversionCommon Stock | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015842 · form4.xml · nonDerivative · entry 1 WOLD OLSEN PER · CIK 0001181185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:30 UTC |
Whitley Richard JamesDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015845 · form4.xml · derivative · entry 2 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,028 Underlying: Common Stock · 2,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 5, 2020. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 5, 2020. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:30 UTC |
Whitley Richard JamesDirector
|
Exercise / conversionCommon Stock | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015845 · form4.xml · nonDerivative · entry 1 Whitley Richard James · CIK 0001441661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:36 UTC |
MANWANI HARISHDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015849 · form4.xml · derivative · entry 3 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vested on May 5, 2020. F2 · derivative.expiration_date: 100% of the restricted stock units will vested on May 5, 2020. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:36 UTC |
MANWANI HARISHDirector
|
Tax withholdingCommon Stock | 419 | $79.14 | $33,159.66 |
DisclosureSEC source: 0001127602-20-015849 · form4.xml · nonDerivative · entry 2 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,718 Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:36 UTC |
MANWANI HARISHDirector
|
Exercise / conversionCommon Stock | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015849 · form4.xml · nonDerivative · entry 1 MANWANI HARISH · CIK 0001527726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:28 UTC |
Cogan John FrancisDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,416 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-015427 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,416 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:28 UTC |
Cogan John FrancisDirector
|
SaleCommon Stock | 2,416 | $81.75 | $197,508.00 |
DisclosureSEC source: 0001127602-20-015427 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:28 UTC |
Cogan John FrancisDirector
|
Exercise / conversionCommon Stock | 2,416 | $19.63 | $47,426.08 |
DisclosureSEC source: 0001127602-20-015427 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:40 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 11,486 | $0.00 Strike: $66.36 | $0.00 |
DisclosureSEC source: 0001127602-20-015665 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,829 Underlying: Common Stock · 11,486 shares Expires 2027-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:40 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
SaleCommon Stock | 12,264 | $80.09 | $982,220.08 |
DisclosureSEC source: 0001127602-20-015665 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,421 F2 · price: Sale prices reported for the transactions reported here range from $80.07 to $80.14. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:40 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 11,486 | $66.36 | $762,210.96 |
DisclosureSEC source: 0001127602-20-015665 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:28 UTC |
Cogan John FrancisDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-014714 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,416 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:28 UTC |
Cogan John FrancisDirector
|
SaleCommon Stock | 2,413 | $79.90 | $192,798.70 |
DisclosureSEC source: 0001127602-20-014714 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 23:28 UTC |
Cogan John FrancisDirector
|
Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-014714 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 23:42 UTC |
Cogan John FrancisDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-014247 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,829 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 23:42 UTC |
Cogan John FrancisDirector
|
SaleCommon Stock | 2,413 | $83.00 | $200,279.00 |
DisclosureSEC source: 0001127602-20-014247 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| April 20, 2020 Filed Apr 21, 2020 23:42 UTC |
Cogan John FrancisDirector
|
Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-014247 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 13, 2020 Filed Apr 14, 2020 19:52 UTC |
Cogan John FrancisDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001127602-20-013679 · form4.xml · derivative · entry 3 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,242 Underlying: Common Stock · 2,413 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. Read SEC document |
| April 13, 2020 Filed Apr 14, 2020 19:52 UTC |
Cogan John FrancisDirector
|
SaleCommon Stock | 2,413 | $75.90 | $183,146.70 |
DisclosureSEC source: 0001127602-20-013679 · form4.xml · nonDerivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,860 Read SEC document |
| April 13, 2020 Filed Apr 14, 2020 19:52 UTC |
Cogan John FrancisDirector
|
Exercise / conversionCommon Stock | 2,413 | $19.63 | $47,367.19 |
DisclosureSEC source: 0001127602-20-013679 · form4.xml · nonDerivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.